News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
It is the first autotaxin inhibitor to be investigated in cancer patients
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Subscribe To Our Newsletter & Stay Updated
